Home

Articles from Geneticure Inc.

Geneticure Inc. Granted New U.S. Patent for Genetic Test to Predict Response in Renal Denervation for Hypertension
Geneticure Inc., a leader in precision medicine for cardiovascular disease, announced today that the United States Patent and Trademark Office has granted U.S. Patent No. 12,351,873, for a Genetic-Based Weighted Algorithm Model for Predicting Response to Renal Denervation. This groundbreaking patent protects Geneticure’s proprietary method of using a patient’s genetic profile to predict their likelihood of benefiting from renal denervation — a minimally invasive procedure used to treat hypertension.
By Geneticure Inc. · Via Business Wire · July 10, 2025